Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants. Richardson RA, Moon C, Sands CM, Nelson R, et al. Vaccine 2025;72:128028.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Richardson RA, Moon C, Sands CM, Nelson R, et al. Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants. Vaccine 2025;72:128028.
PMID: 41351929